Diabetes Type 2

HbA1c levels over time were found higher at initiation of second-line treatment in veterans aged 55 years and younger, a trend unsettling to a new study's lead author.

SAMPLE: What was the first FDA-approved CGM system to include a fully implantable sensor to detect glucose?

Initiation of second-line type 2 diabetes treatment is lagging while A1c at the time it is introduced is climbing. The author of a new study highlights his findings on clinical inertia.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

Treatment with intranasal insulin improved executive function and verbal memory, as well as other measures, in participants with and without type 2 diabetes.

The ONWARDS 2 trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 26 with insulin icodec vs insulin degludec.

Researchers developed polygenic risk scores for 6 common diseases and informational resources to help primary care physicians incorporate them into clinical practice.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.